Dmitrii Shkil

Dr. Dmitrii Shkil

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2021 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
EYEmil Yamansarov
Emil Yamansarov
ELElena V. Lopatukhina
Elena V. Lopatukhina
SESergei A. Evteev
Sergei A. Evteev
DSDmitry A. Skvortsov
Dmitry A. Skvortsov
ALAnton V. Lopukhov
Anton V. Lopukhov
AMAlexander G. Majouga
Alexander G. Majouga

Verified
Journal Article
Open access
PDF file
AIAlexandre V. Ivachtchenko
Alexandre V. Ivachtchenko
AIAndrey A. Ivashchenko
Andrey A. Ivashchenko
DSDmitrii Shkil
Dmitrii Shkil
IIIlya A. Ivashchenko
Ilya A. Ivashchenko
Aprotinin (APR) was discovered in 1930. APR is an effective pan-protease inhibitor, a typical “magic shotgun”. Until 2007, APR was widely used as an antithrombotic and anti-inflammatory drug in cardiac and noncardiac surgeries for reduction of bleeding and thus limiting the need for blood transfusion. The ability of APR to inhibit proteolytic activation of some viruses leads to its use as an antiviral drug for the prevention and treatment of acute respiratory virus infections. However, due to incompetent interpretation of several clinical trials followed by incredible controversy in the literature, the usage of APR was nearly stopped for a decade worldwide. In 2015–2020, after re-analysis of these clinical trials’ data the restrictions in APR usage were lifted worldwide. This review discusses antiviral mechanisms of APR action and summarizes current knowledge and prospective regarding the use of APR treatment for diseases caused by RNA-containing viruses, including influenza and SARS-CoV-2 viruses, or as a part of combination antiviral treatment.

1 April 2019 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
EYEmil Yamansarov
Emil Yamansarov
ISI. V. Saltykova
I. V. Saltykova
SKS. V. Kovalev
S. V. Kovalev
RPRostislav Petrov
Rostislav Petrov
DSDmitrii Shkil
Dmitrii Shkil
AMA. G. Majouga
A. G. Majouga

17 April 2024 in Molecules
Verified
Journal Article
Open access
PDF file
DSDmitrii Shkil
Dmitrii Shkil
AMAlina A. Muhamedzhanova
Alina A. Muhamedzhanova
PPPhilipp I. Petrov
Philipp I. Petrov
ESEkaterina Skorb
Ekaterina Skorb
TATimur A. Aliev
Timur A. Aliev
MFMaxim Fedorov
Maxim Fedorov
In the realm of predictive toxicology for small molecules, the applicability domain of QSAR models is often limited by the coverage of the chemical space in the training set. Consequently, classical models fail to provide reliable predictions for wide classes of molecules. However, the emergence of innovative data collection methods such as intensive hackathons have promise to quickly expand the available chemical space for model construction. Combined with algorithmic refinement methods, these tools can address the challenges of toxicity prediction, enhancing both the robustness and applicability of the corresponding models. This study aimed to investigate the roles of gradient boosting and strategic data aggregation in enhancing the predictivity ability of models for the toxicity of small organic molecules. We focused on evaluating the impact of incorporating fragment features and expanding the chemical space, facilitated by a comprehensive dataset procured in an open hackathon. We used gradient boosting techniques, accounting for critical features such as the structural fragments or functional groups often associated with manifestations of toxicity.

1 May 2019 in Mendeleev Communications
Verified
Journal Article
Closed access
BPBoris I. Podlovchenko
Boris I. Podlovchenko
YMYurii M. Maksimov
Yurii M. Maksimov
DSDmitrii Shkil
Dmitrii Shkil
Galvanic displacement of electrodeposited lead by palladium fails to produce Pd shells. The anomalous ratio between formic acid electrooxidation reaction (FAOR) rates on Pd0(Pb) observed in HClO4 and H2SO4 solutions is associated with the reduction of ClO4− anions to chloride ones which inhibit the FAOR.

9 May 2026 in Molecules
Verified
Journal Article
Open access
PDF file
DSDmitrii Shkil
Dmitrii Shkil
NCNatalia Chesnokova
Natalia Chesnokova
AIAndrey A. Ivashchenko
Andrey A. Ivashchenko
EPElena Vladimirovna Petersen
Elena Vladimirovna Petersen
PMPhilipp Y. Maximov
Philipp Y. Maximov
Selective inhibition of poly(ADP-ribose) polymerase 1 (PARP1) may reduce the hematologic toxicity associated with dual PARP1/PARP2 inhibition. We performed molecular dynamics simulations for five selective inhibitors in complexes with PARP1 and PARP2, using three independent 50 ns runs per complex after docking and equilibration, followed by protein–ligand interaction fingerprint and statistical analyses. All complexes remained dynamically stable, with ligand root-mean-square deviation values generally within 0.3 nm. Comparative analysis identified three αF-helix residue pairs with nominally reduced interaction frequencies in PARP2: Asn767/Ala336, Leu769/Gly338, and Asp770/Asp339 (p < 0.05). After Benjamini–Hochberg correction for multiple comparisons, Leu769/Gly338 remained significant (q < 0.05), indicating that this pair represents the most statistically robust interaction difference within this region. Using palacaparib as the most selective inhibitor, these differences were associated with weakened or lost hydrophobic, van der Waals, and cation–π interactions in PARP2. Selective binding of modern PARP1 inhibitors appears to be associated with αF-helix-dependent interaction patterns, providing a mechanistic basis for the rational design of next-generation selective inhibitors with improved selectivity and potentially reduced toxicity.